Effects of prophylactic use of sirolimus on bronchiolitis obliterans syndrome development in lung transplant recipients

Annals of Thoracic Surgery

Volumn 97, Issue 1, 2014, Pages 268-274

  Sacher, Vikas Y ^a   Fertel, Debra ^b   Srivastava, Karan ^a   Panos, Anthony ^a   Nguyen, Dao ^a   Baxter, Tammy ^a   Shafazand, Shirin ^a   Pham, Si M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b University of Miami Jackson Memorial Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYTOMEGALOVIRUS ANTIBODY; GANCICLOVIR; HYPERIMMUNE GLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BRONCHIOLITIS OBLITERANS; CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG TOLERANCE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTERSTITIAL PNEUMONIA; KAPLAN MEIER METHOD; KIDNEY FAILURE; LEUKOPENIA; LONG TERM CARE; LUNG FUNCTION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAINTENANCE THERAPY; MALE; MIDDLE AGED; NEOPLASM; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; RASH; RETROSPECTIVE STUDY; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; VIRUS INFECTION;

EID: 84891602207     PISSN: 00034975     EISSN: 15526259     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2013.07.072     Document Type: Article

References (28)

1. M. Estenne, J.R. Maurer, and A. Boehler et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria J Heart Lung Transplant 21 2002 297 310
2. J.D. Christie, L.B. Edwards, and A.Y. Kucheryavaya et al. The registry of the international society for heart and lung transplantation: 29th adult lung and heart-lung transplant report-2012 J Heart Lung Transplant 31 2012 1073 1086
3. A. Mehrabi, H. Fonouni, and A. Kashfi et al. The role and value of sirolimus administration in kidney and liver transplantation Clin Transplant 20 2006 30 43
4. M. Viganò, M. Tuzcu, and R. Benza et al. Prevention of acute rejection and allograft vasculopathy by everolimus in cardiac transplant recipients: a 24 month analysis J Heart Lung Transplant 26 2007 584 592
5. S.N. Sehgal Sirolimus: its discovery, biological properties, and mechanism of action Transplant Proc 35 3 Suppl 2003 7S 14S
6. H. Kreis, J. Cisterne, and W. Land et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients Transplantation 69 2000 1252 1260
7. M.B. King-Biggs, J.M. Dunitz, S.J. Park, S. Kay Savik, and M.I. Hertz Airway anastomotic dehiscence associated with use of sirolimus immediately after lung transplantation Transplantation 75 2003 1437 1443
8. R.L. Hernández, P.U. Gil, C.G. Gallo, A. de Pablo Gafas, M.C. Hernández, and M.J. Alvarez Rapamycin in lung transplantation Transplant Proc 37 2005 3999 4000
9. P. Ussetti, R. Laporta, A. de Pablo, C. Carreño, J. Segovia, and L. Pulpón Rapamycin in lung transplantation: preliminary results Transplant Proc 35 2003 1974 1977
10. B.C. Cahill, K.T. Somerville, and J.A. Crompton et al. Early experience with sirolimus in lung transplant recipients with chronic allograft rejection J Heart Lung Transplant 22 2003 169 176
11. G.I. Snell, B.J. Levvey, and W. Chin et al. Sirolimus allows renal recovery in lung and heart transplant recipients with chronic renal impairment J Heart Lung Transplant 21 2002 540 546
12. S. Bhorade, V.N. Ahya, and M.A. Baz et al. Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation Am J Respir Crit Care Med 183 2011 379 387
13. V.N. Ahya, P.J. McShane, and M.A. Baz et al. Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation J Heart Lung Transplant 30 2011 175 181
14. V.C. McAlister, Z. Gao, K. Peltekian, J. Domingues, K. Mahalati, and A.S. Macdonald Sirolimus-tacrolimus combination immunosuppression Lancet 355 2000 376 377
15. S.A. Yousem, G.J. Berry, and P.T. Cagle et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group J Heart Lung Transplant 15 1 Pt 1 1996 1
16. G.M. Verleden, R. Vos, and S.I. De Vleeschauwer et al. Obliterative bronchiolitis following lung transplantation: from old to new concepts? Transpl Int 22 2009 771 779
17. R.S. Poston, M. Billingham, and G. Hoyt et al. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model Circulation 100 1999 67 74
18. O. Viklický, H. Zou, V. Müller, J. Lacha, A. Szabó, and U. Heemann SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts Transplantation 69 2000 497 502
19. J.A. Fahrni, G.J. Berry, R.E. Morris, and G.D. Rosen Rapamycin inhibits development of obliterative airway disease in a murine heterotopic airway transplant model Transplantation 63 1997 533 537
20. R. Nair, X. Huang, and R. Shorthouse et al. Antiproliferative effect of rapamycin on growth factor-stimulated human adult lung fibroblasts in vitro may explain its superior efficacy for prevention and treatment of allograft obliterative airway disease in vivo Transplant Proc 29 1997 614 615
21. J. Villanueva, A. Boukhamseen, and S.M. Bhorade Successful use in lung transplantation of an immunosuppressive regimen aimed at reducing target blood levels of sirolimus and tacrolimus J Heart Lung Transplant 24 2005 421 424
22. B.R. Stephany, M. Boumitri, M. Budev, B. Alao, and E.D. Poggio Absence of proteinuria predicts improvement in renal function after conversion to sirolimus-based immunosuppressive regimens in lung transplant survivors with chronic kidney disease J Heart Lung Transplant 28 2009 564 571
23. R. Lischke, J. Simonek, and K. Matousovic et al. Initial single-center experience with sirolimus after lung transplantation Transplantation Proc 38 2006 3006 3011
24. F. Venuta, T. De Giacomo, and E.A. Rendina et al. Recovery of chronic renal impairment with sirolimus after lung transplantation Ann Thorac Surg 78 2004 1940 1943
25. D. Shitrit, R. Rahamimov, and S. Gidon et al. Use of sirolimus and low-dose calcineurin inhibitor in lung transplant recipients with renal impairment: results of a controlled pilot study Kidney Int 67 2005 1471 1475
26. H.U. Meier-Kriesche, and B. Kaplan Toxicity and efficacy of sirolimus: relationship to whole-blood concentrations Clin Ther 22 Suppl B 2000 B93 B100
27. J.A. Muldowney III, J.R. Stringham, and S.E. Levy et al. Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents Arterioscler Thromb Vasc Biol 27 2007 400 406
28. S. Garrean, M.G. Massad, M. Tshibaka, Z. Hanhan, A.E. Caines, and E. Benedetti Sirolimus-associated interstitial pneumonitis in solid organ transplant recipients Clin Transplant 19 2005 698 703